GlassScriptPhysician profile
Thomas M Tran
NPI 1811959190
$10,632.20
in general payments reported to CMS, 2019-2025
30 companies · $1,170 in 2025
The $1,170 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,015 · 2020: $2,237 · 2021: $2,185 · 2022: $1,010 · 2023: $968 · 2024: $1,050 · 2025: $1,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,186.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,533.06 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,565.53 | 2019-2025 | Repatha, Otezla, Otezla |
| Amarin Pharma, INC. | $980.18 | 2019-2022 | |
| Novo Nordisk INC | $948.48 | 2019-2024 | Rybelsus, Ozempic |
| Nestle Healthcare Nutrition INC. | $601.65 | 2020-2023 | |
| Lilly USA, LLC | $427.58 | 2020-2024 | Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.80 | 2019-2024 | Jardiance |
| Abbvie INC. | $369.54 | 2019-2024 | |
| Pfizer INC. | $317.82 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $256.71 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Sunovion Pharmaceuticals INC. | $246.45 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $198.08 | 2021-2022 | |
| Horizon Therapeutics Plc | $170.60 | 2019-2022 | |
| Astellas Pharma US INC | $160.12 | 2019-2020 | |
| Mylan Specialty L.P. | $156.78 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $154.06 | 2019-2020 | |
| Zyla Life Sciences, INC. | $128.71 | 2019 | |
| Glaxosmithkline, LLC. | $126.51 | 2019-2021 | |
| Exact Sciences Corporation | $124.99 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $112.61 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $109.82 | 2024-2025 | Zenpep |
| Gilead Sciences, INC. | $102.35 | 2020-2021 | |
| Radius Health, INC. | $99.99 | 2019 | |
| Sumitomo Pharma America, INC. | $91.09 | 2024-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $84.98 | 2019-2023 | |
| Eisai INC. | $65.91 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.56 | 2019 | |
| Abbott Laboratories | $44.89 | 2020-2021 | |
| Assertio Therapeutics, INC. | $16.35 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.